{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:17:54Z","timestamp":1794489474865,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-025-06565-1","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T11:06:59Z","timestamp":1741691219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinician differences in attitudes and perceptions on the use of long-acting injectable antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE survey"],"prefix":"10.1186","volume":"25","author":[{"given":"Dawn","family":"Velligan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Belcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli R.","family":"Franzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Rolf T.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"5","key":"6565_CR1","doi-asserted-by":"publisher","first-page":"IN18031AH18031C","DOI":"10.4088\/JCP.IN18031AH1C","volume":"80","author":"JM Kane","year":"2019","unstructured":"Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5):IN18031AH18031C.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 4","key":"6565_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.7090su1cj","volume":"70","author":"DI Velligan","year":"2009","unstructured":"Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1\u201346.","journal-title":"J Clin Psychiatry"},{"key":"6565_CR3","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/PPA.S53795","volume":"7","author":"G Kaplan","year":"2013","unstructured":"Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171\u201380.","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"6565_CR4","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1007\/s12325-022-02232-z","volume":"39","author":"A Martin","year":"2022","unstructured":"Martin A, Bessonova L, Hughes R, Doane MJ, O\u2019Sullivan AK, Snook K, Cichewicz A, Weiden PJ, Harvey PD. Systematic review of real-world treatment patterns of oral antipsychotics and associated economic burden in patients with schizophrenia in the United States. Adv Therapy. 2022;39(9):3933\u201356.","journal-title":"Adv Therapy"},{"issue":"4","key":"6565_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1034\/j.1600-0447.2002.02437.x","volume":"106","author":"EL Coldham","year":"2002","unstructured":"Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica. 2002;106(4):286\u201390.","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"10","key":"6565_CR6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"6565_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","volume":"16","author":"M Carbon","year":"2014","unstructured":"Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialog Clin Neurosci. 2014;16(4):505\u201324.","journal-title":"Dialog Clin Neurosci"},{"issue":"8","key":"6565_CR8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","volume":"55","author":"PJ Weiden","year":"2004","unstructured":"Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Serv (Washington DC). 2004;55(8):886\u201391.","journal-title":"Psychiatric Serv (Washington DC)"},{"issue":"1\u20133","key":"6565_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.schres.2006.11.015","volume":"90","author":"G Remington","year":"2007","unstructured":"Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res. 2007;90(1\u20133):229\u201337.","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"6565_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.psychres.2004.11.002","volume":"133","author":"M Byerly","year":"2005","unstructured":"Byerly M, Fisher R, Whatley K, Holland R, Varghese F, Carmody T, Magouirk B, Rush AJ. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005;133(2\u20133):129\u201333.","journal-title":"Psychiatry Res"},{"issue":"1","key":"6565_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40261-020-00990-8","volume":"41","author":"J Mahlich","year":"2021","unstructured":"Mahlich J, Olbrich K, Wilk A, Wimmer A, Wolff-Menzler C. Time to treatment discontinuation in German patients with schizophrenia: long-acting injectables versus oral antipsychotics. Clin Drug Investig. 2021;41(1):99\u2013113.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"6565_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/eip.13384","volume":"17","author":"S Schwartz","year":"2023","unstructured":"Schwartz S, Lee S, Coble EB, Troxler C, Toscano S, Kumar A. Time-to-therapy discontinuation in patients newly diagnosed with schizophrenia initiated on long-acting injectable versus oral dopamine receptor blocking agents. Early Interv Psychiat. 2023;17(9):921\u20138.","journal-title":"Early Interv Psychiat"},{"issue":"5","key":"6565_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/YIC.0b013e328354b534","volume":"27","author":"EJ Duncan","year":"2012","unstructured":"Duncan EJ, Woolson SL, Hamer RM. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable. Int Clin Psychopharmacol. 2012;27(5):283\u201390.","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"6565_CR14","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1007\/s12325-018-0786-x","volume":"35","author":"A Shah","year":"2018","unstructured":"Shah A, Xie L, Kariburyo F, Zhang Q, Gore M. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. Adv Therapy. 2018;35(11):1994\u20132014.","journal-title":"Adv Therapy"},{"issue":"3","key":"6565_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clinthera.2021.01.011","volume":"43","author":"M Zhdanava","year":"2021","unstructured":"Zhdanava M, Lin D, Lafeuille MH, Ghelerter I, Morrison L, Lefebvre P, Joshi K. Antipsychotic adherence, resource use, and costs before and after the initiation of once-monthly paliperidone palmitate therapy among Medicaid beneficiaries with prior schizophrenia relapse. Clin Ther. 2021;43(3):535\u201348.","journal-title":"Clin Ther"},{"issue":"1","key":"6565_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40801-019-00172-9","volume":"7","author":"C Patel","year":"2020","unstructured":"Patel C, Emond B, Lafeuille MH, C\u00f4t\u00e9-Sergent A, Lefebvre P, Tandon N, El Khoury AC. Real-world analysis of switching patients with schizophrenia from oral risperidone or oral paliperidone to once-monthly paliperidone palmitate. Drugs - real World Outcomes. 2020;7(1):19\u201329.","journal-title":"Drugs - real World Outcomes"},{"issue":"1","key":"6565_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12325-022-02354-4","volume":"40","author":"MC Dickson","year":"2023","unstructured":"Dickson MC, Nguyen MM, Patel C, Grabich SC, Benson C, Cothran T, Skrepnek GH. Adherence, persistence, readmissions, and costs in Medicaid members with schizophrenia or schizoaffective disorder initiating paliperidone palmitate versus switching oral antipsychotics: a real-world retrospective investigation. Adv Therapy. 2023;40(1):349\u201366.","journal-title":"Adv Therapy"},{"issue":"7","key":"6565_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Meht\u00e4l\u00e4 J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686\u201393.","journal-title":"JAMA Psychiatry"},{"key":"6565_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12991-019-0254-2","volume":"19","author":"HO Kim","year":"2020","unstructured":"Kim HO, Seo GH, Lee BC. Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia. Ann Gen Psychiatry. 2020;19:1.","journal-title":"Ann Gen Psychiatry"},{"issue":"5","key":"6565_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"6565_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40263-022-00917-1","volume":"36","author":"L Guti\u00e9rrez-Rojas","year":"2022","unstructured":"Guti\u00e9rrez-Rojas L, S\u00e1nchez-Alonso S, Garc\u00eda Dorado M, L\u00f3pez Rengel PM. Impact of 3-monthly long-acting injectable paliperidone palmitate in schizophrenia: a retrospective, real-world analysis of population-based health records in Spain. CNS Drugs. 2022;36(5):517\u201327.","journal-title":"CNS Drugs"},{"key":"6565_CR22","unstructured":"Velligan D, Salinas GD, Belcher E, Franzenburg KR, Suett M, Thompson S, Hansen RT III. Differences between high and low users of long-acting injectable antipsychotics for patients with schizophrenia: a survey of US-practicing psychiatric clinicians. In: 18th Annual NEI Psychopharmacology Congress. November 3\u20136, 2022 edn. Colorado Springs, Colorado; 2022."},{"key":"6565_CR23","doi-asserted-by":"publisher","first-page":"204512532211225","DOI":"10.1177\/20451253221122526","volume":"12","author":"C Montemagni","year":"2022","unstructured":"Montemagni C, Del Favero E, Cocuzza E, Vischia F, Rocca P. Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study. Therapeutic Adv Psychopharmacol. 2022;12:20451253221122526.","journal-title":"Therapeutic Adv Psychopharmacol"},{"issue":"9","key":"6565_CR24","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1080\/03007995.2022.2101819","volume":"38","author":"LM Tidmore","year":"2022","unstructured":"Tidmore LM, Keast SL, Waters HC, Pareja KL, Cothran T, Skrepnek GH. Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia. Curr Med Res Opin. 2022;38(9):1621\u201330.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"6565_CR25","doi-asserted-by":"publisher","first-page":"21r14153","DOI":"10.4088\/JCP.21r14153","volume":"83","author":"SC Fang","year":"2022","unstructured":"Fang SC, Huang CY, Shao YJ. Long-term outcomes of early use of long-acting injectable antipsychotics in schizophrenia. J Clin Psychiatry. 2022;83(4):21r14153.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"6565_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/YIC.0000000000000339","volume":"36","author":"JA Garc\u00eda-Carmona","year":"2021","unstructured":"Garc\u00eda-Carmona JA, Simal-Aguado J, Campos-Navarro MP, Valdivia-Mu\u00f1oz F, Galindo-Tovar A. Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain. Int Clin Psychopharmacol. 2021;36(1):18\u201324.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"6565_CR27","doi-asserted-by":"publisher","first-page":"e218810","DOI":"10.1001\/jamanetworkopen.2021.8810","volume":"4","author":"CY Huang","year":"2021","unstructured":"Huang CY, Fang SC, Shao YJ. Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia. JAMA Netw open. 2021;4(5):e218810.","journal-title":"JAMA Netw open"},{"issue":"1","key":"6565_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jagp.2019.08.005","volume":"28","author":"CH Lin","year":"2020","unstructured":"Lin CH, Chen FC, Chan HY, Hsu CC. A comparison of long-acting injectable antipsychotics with oral antipsychotics on time to rehospitalization within 1 year of discharge in elderly patients with schizophrenia. Am J Geriatric Psychiatry: Official J Am Association Geriatric Psychiatry. 2020;28(1):23\u201330.","journal-title":"Am J Geriatric Psychiatry: Official J Am Association Geriatric Psychiatry"},{"issue":"4","key":"6565_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14656566.2023.2181073","volume":"24","author":"PM Haddad","year":"2023","unstructured":"Haddad PM, Correll CU. Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. Expert Opin Pharmacother. 2023;24(4):473\u201393.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"6565_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12888-022-03846-x","volume":"22","author":"A Keenan","year":"2022","unstructured":"Keenan A, Lin D, Shepherd J, Bailey H, Benson C, Meakin S. Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey. BMC Psychiatry. 2022;22(1):187.","journal-title":"BMC Psychiatry"},{"key":"6565_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/NDT.S326299","volume":"18","author":"L Citrome","year":"2022","unstructured":"Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD. Management of schizophrenia with long-acting injectable antipsychotic medications: an assessment of the educational needs of clinicians. Neuropsychiatr Dis Treat. 2022;18:111\u201323.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6565_CR32","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/NDT.S369494","volume":"18","author":"M Zhdanava","year":"2022","unstructured":"Zhdanava M, Starr HL, Lefebvre P, Totev TI, Shah A, Sheng K, Pilon D. Understanding the health system conditions affecting the use of long-acting injectable antipsychotics in the treatment of schizophrenia in clinical practice: a US healthcare provider survey. Neuropsychiatr Dis Treat. 2022;18:1479\u201393.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"6565_CR33","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"6565_CR34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12888-023-04928-0","volume":"23","author":"C Arango","year":"2023","unstructured":"Arango C, Fagiolini A, Gorwood P, Kane JM, Diaz-Mendoza S, Sahota N, Correll CU. Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery. BMC Psychiatry. 2023;23(1):453.","journal-title":"BMC Psychiatry"},{"key":"6565_CR35","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2147\/NDT.S167394","volume":"14","author":"M Sajatovic","year":"2018","unstructured":"Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, Fitzgerald H, Byerly M. Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1. Neuropsychiatr Dis Treat. 2018;14:1463\u201374.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"6565_CR36","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s12325-023-02455-8","volume":"40","author":"DG Robinson","year":"2023","unstructured":"Robinson DG, Suett M, Wilhelm A, Chaijale N, Franzenburg KR, Gandhi S, Cloud B, Mychaskiw M. Patient and healthcare professional preferences for characteristics of long-acting injectable antipsychotic agents for the treatment of schizophrenia. Adv Therapy. 2023;40(5):2249\u201364.","journal-title":"Adv Therapy"},{"key":"6565_CR37","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.2147\/NDT.S167485","volume":"14","author":"M Sajatovic","year":"2018","unstructured":"Sajatovic M, Ross R, Legacy SN, Byerly M, Kane JM, DiBiasi F, Fitzgerald H, Correll CU. Initiating\/maintaining long-acting injectable antipsychotics in schizophrenia\/schizoaffective or bipolar disorder - expert consensus survey part 2. Neuropsychiatr Dis Treat. 2018;14:1475\u201392.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"6565_CR38","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40263-016-0350-7","volume":"30","author":"E Parellada","year":"2016","unstructured":"Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30(8):689\u2013701.","journal-title":"CNS Drugs"},{"key":"6565_CR39","unstructured":"Monaghan S, Zhdanava M, Lefebvre P, Totev TI, Obando C, Shah A, Baker P, Starr HL, Pilon D. Understanding characteristics of healthcare providers with higher-than-average rates of prescribing long-acting injectable antipsychotics: a US healthcare provider survey. In: 34th Annual Psych Congress. October 29-November 1, 2021 edn. San Antonio, Texas; 2021."},{"key":"6565_CR40","unstructured":"Teva Neuroscience, Inc. UzedyTM (risperidone) extended-release injectable suspension. Parsippany, NJ; 2024."},{"key":"6565_CR41","unstructured":"Janssen Pharmaceutical Companies. Invega Sustenna\u00ae (paliperidone palmitate) extended-release injectable suspension. 2021."},{"key":"6565_CR42","unstructured":"Janssen Pharmaceutical Companies. Risperdal Consta\u00ae (risperidone) long-acting injection. Titusville, NJ; 2021."},{"issue":"9","key":"6565_CR43","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S2215-0366(20)30264-9","volume":"7","author":"JM Rubio","year":"2020","unstructured":"Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, Malhotra AK, Correll CU, Kane JM. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry. 2020;7(9):749\u201361.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"6565_CR44","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1176\/ps.2007.58.6.844","volume":"58","author":"MJ Byerly","year":"2007","unstructured":"Byerly MJ, Thompson A, Carmody T, Bugno R, Erwin T, Kashner M, Rush AJ. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatric Serv (Washington DC). 2007;58(6):844\u20137.","journal-title":"Psychiatric Serv (Washington DC)"},{"issue":"6","key":"6565_CR45","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1742-1241.2012.02918.x","volume":"66","author":"JJ Stephenson","year":"2012","unstructured":"Stephenson JJ, Tunceli O, Gu T, Eisenberg D, Panish J, Crivera C, Dirani R. Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians\u2019 perceptions of adherence vs. pharmacy claims. Int J Clin Pract. 2012;66(6):565\u201373.","journal-title":"Int J Clin Pract"},{"issue":"9","key":"6565_CR46","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1176\/ps.2007.58.9.1187","volume":"58","author":"DI Velligan","year":"2007","unstructured":"Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, Lam YW, Ereshefsky L, Miller AL. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatric Serv (Washington DC). 2007;58(9):1187\u201392.","journal-title":"Psychiatric Serv (Washington DC)"},{"issue":"6","key":"6565_CR47","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/JCP.0000000000001109","volume":"39","author":"S Grover","year":"2019","unstructured":"Grover S, Sahoo S, Mehra A. Perceptions of psychiatrists toward the Use of Long-Acting Injectable antipsychotics: an Online Survey Study from India. J Clin Psychopharmacol. 2019;39(6):611\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"6565_CR48","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3390\/ijms17111935","volume":"17","author":"L Samalin","year":"2016","unstructured":"Samalin L, Garnier M, Auclair C, Llorca PM. Clinical decision-making in the treatment of schizophrenia: focus on long-acting injectable antipsychotics. Int J Mol Sci. 2016;17(11):1935.","journal-title":"Int J Mol Sci"},{"key":"6565_CR49","doi-asserted-by":"crossref","unstructured":"Franzenburg KR III, Suett HR, Yaari M, Levin A, Sergerie AP, Gonzalez M, Sedigh A, Heres K, Sajatovic S. M: Patient and caregiver perspectives on using Long-Acting Injectable antipsychotics to treat Schizophrenia: Survey results from the multinational ADVANCE study. Presented at the 37th European College of Neuropsychopharmacology Congress; September 21\u201324, 2024; Milan, Italy.","DOI":"10.1016\/j.nsa.2024.104606"},{"key":"6565_CR50","doi-asserted-by":"crossref","unstructured":"Franzenburg KR III, Suett HR, Yaari M, Sergerie A, Kaplan M, Gonzalez S, Sedigh A, Heres K, Sajatovic S. M: Experiences and perceptions of Healthcare Professionals with Long-Acting Injectable Antipsychotic Use in Schizophrenia: Survey results from the multinational ADVANCE study. Presented at the 37th European College of Neuropsychopharmacology Congress; September 21\u201324, 2024; Milan, Italy.","DOI":"10.1016\/j.nsa.2024.105008"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06565-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06565-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06565-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:05:17Z","timestamp":1741694717000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06565-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6565"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06565-1","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempted from institutional review board oversight by Western Institutional Review Board (Puyallup, WA) under the Common Rule 45 CFR \u00a7\u00a046.104(d)(2) (research only included interactions involving survey procedures, and there were adequate provisions to maintain participant privacy and confidentiality). Respondents provided informed consent prior to completing the survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dawn Velligan has received medical writing support from CE Outcomes; consulting fees from Alkermes, Janssen, and Otsuka; travel support from Alkermes and Otsuka; and advisory board support from Janssen, Merck, and Otsuka. Gregory D Salinas and Emily Belcher are employees of CE Outcomes, LLC, which has received payments from Teva Pharmaceuticals in relation to this study. Kelli R Franzenburg, Mark Suett, Stephen Thompson, and Rolf T Hansen III are employees and shareholders of Teva Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}